Patrick J. Flynn

18.9k total citations · 3 hit papers
145 papers, 11.1k citations indexed

About

Patrick J. Flynn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Patrick J. Flynn has authored 145 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 26 papers in Genetics. Recurrent topics in Patrick J. Flynn's work include Colorectal Cancer Treatments and Studies (31 papers), Cancer Treatment and Pharmacology (28 papers) and Glioma Diagnosis and Treatment (17 papers). Patrick J. Flynn is often cited by papers focused on Colorectal Cancer Treatments and Studies (31 papers), Cancer Treatment and Pharmacology (28 papers) and Glioma Diagnosis and Treatment (17 papers). Patrick J. Flynn collaborates with scholars based in United States, Canada and China. Patrick J. Flynn's co-authors include Al B. Benson, Mark R. Somerfield, Gary R. Morrow, Charles L. Loprinzi, Kendrith M. Rowland, Kurt A. Jaeckle, Jeffrey J. Kirshner, Shaker R. Dakhil, Joseph A. Roscoe and Jan C. Buckner and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Patrick J. Flynn

145 papers receiving 10.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

2004 1.1k citations Al B. Benson, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

2011 604 citations Patrick J. Loehrer, Yang Feng et al. Journal of Clinical Oncology profile →
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

2010 500 citations Patrick J. Flynn, Kendrith M. Rowland et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick J. Flynn United States	51	6.9k	2.6k	2.2k	2.2k	1.6k	145	11.1k
Shaker R. Dakhil United States	60	9.2k 1.3×	5.1k 1.9×	3.3k 1.5×	3.0k 1.4×	3.1k 2.0×	313	16.4k
Aung Naing United States	58	5.8k 0.8×	3.0k 1.1×	4.4k 2.0×	1.4k 0.6×	3.0k 2.0×	483	12.5k
Vera J. Suman United States	60	7.0k 1.0×	2.3k 0.9×	3.0k 1.4×	1.7k 0.8×	3.6k 2.3×	273	14.8k
Javid J. Moslehi United States	68	6.6k 1.0×	2.2k 0.8×	3.7k 1.7×	794 0.4×	1.3k 0.8×	211	16.0k
Sandro Barni Italy	61	7.7k 1.1×	4.3k 1.7×	1.9k 0.9×	1.5k 0.7×	2.0k 1.3×	479	14.5k
Siqing Fu United States	51	4.1k 0.6×	2.4k 0.9×	3.8k 1.7×	1.2k 0.6×	2.4k 1.6×	412	9.6k
Nicholas Pavlidis Greece	60	8.7k 1.3×	2.4k 0.9×	2.3k 1.0×	3.0k 1.3×	1.7k 1.1×	324	13.2k
Hans Wildiers Belgium	54	7.5k 1.1×	3.3k 1.3×	2.7k 1.2×	1000 0.5×	3.4k 2.2×	390	14.6k
Wolff Schmiegel Germany	58	6.2k 0.9×	2.3k 0.9×	4.1k 1.9×	2.2k 1.0×	2.2k 1.4×	267	13.1k
G. Milano France	57	7.8k 1.1×	3.1k 1.2×	4.1k 1.8×	1.4k 0.6×	1.5k 1.0×	392	12.3k

Countries citing papers authored by Patrick J. Flynn

Since Specialization

Citations

This map shows the geographic impact of Patrick J. Flynn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick J. Flynn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick J. Flynn more than expected).

Fields of papers citing papers by Patrick J. Flynn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick J. Flynn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick J. Flynn. The network helps show where Patrick J. Flynn may publish in the future.

Co-authorship network of co-authors of Patrick J. Flynn

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick J. Flynn. A scholar is included among the top collaborators of Patrick J. Flynn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick J. Flynn. Patrick J. Flynn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stearns, Vered, Opeyemi A. Jegede, Victor T. Chang, et al.. (2024). A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11. Clinical Cancer Research. 30(13). 2709–2718. 4 indexed citations

Jaeckle, Kurt A., Erin Twohy, Jesse G. Dixon, et al.. (2019). Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of Neuro-Oncology. 143(3). 573–581. 8 indexed citations

Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations

Yasenchak, Christopher A., Andres Forero‐Torres, Rodolfo Bordoni, et al.. (2015). Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. Blood. 126(23). 587–587. 12 indexed citations

Deplanque, G., Martin Demarchi, Mohamed Hebbar, et al.. (2015). A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Annals of Oncology. 26(6). 1194–1200. 78 indexed citations

Chandwani, Kavita D., Charles E. Heckler, Supriya G. Mohile, et al.. (2014). Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer. EXPLORE. 10(4). 241–247. 10 indexed citations

Daniel, J., Evanthia Galanis, S. Keith Anderson, et al.. (2014). A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology. 17(9). 1261–1269. 122 indexed citations

Galanis, Evanthia, S. Keith Anderson, Joon H. Uhm, et al.. (2013). Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial. Clinical Cancer Research. 19(17). 4816–4823. 127 indexed citations

Tan, Winston, Amylou C. Dueck, Patrick J. Flynn, et al.. (2013). N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Annals of Oncology. 24(10). 2548–2554. 6 indexed citations

10.

Tan, Winston, Jacob B. Allred, Muhammad Salim, et al.. (2012). Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial. Clinical Breast Cancer. 12(2). 81–86. 6 indexed citations

11.

Tan, Antoinette R., Marc Buyse, Priya Rastogi, et al.. (2012). NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).. Journal of Clinical Oncology. 30(15_suppl). 1025–1025. 3 indexed citations

12.

Loehrer, Patrick J., Yang Feng, Higinia R. Cárdenes, et al.. (2011). Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology. 29(31). 4105–4112. 604 indexed citations breakdown →

13.

Kozloff, Mark, Jordan Berlin, Patrick J. Flynn, et al.. (2010). Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study. Oncology. 78(5-6). 329–339. 94 indexed citations

14.

Galanis, E., Kurt A. Jaeckle, Shannon W. Anderson, et al.. (2010). NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.. Journal of Clinical Oncology. 28(15_suppl). 2018–2018. 5 indexed citations

15.

Galanis, Evanthia, Kurt A. Jaeckle, Matthew J. Maurer, et al.. (2009). Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology. 27(12). 2052–2058. 283 indexed citations

16.

Jatoi, Aminah, Shaker R. Dakhil, Nathan R. Foster, et al.. (2008). Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). Journal of Thoracic Oncology. 3(5). 516–520. 26 indexed citations

17.

Kyle, Robert A., Gary C. Yee, Mark R. Somerfield, et al.. (2007). American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma. Journal of Clinical Oncology. 25(17). 2464–2472. 295 indexed citations

18.

Pandya, Kishan J., Gary R. Morrow, Joseph A. Roscoe, et al.. (2005). Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. The Lancet. 366(9488). 818–824. 231 indexed citations

19.

Perez, Edith A., Vera J. Suman, Kendrith M. Rowland, et al.. (2005). Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252. Clinical Breast Cancer. 6(5). 425–432. 99 indexed citations

20.

Jaeckle, Kurt A., Karla V. Ballman, Joon H. Uhm, et al.. (2004). Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials. Journal of Clinical Oncology. 22(14_suppl). 1525–1525. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact